HBIO Harvard Bioscience Inc.

Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025

Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two investor conferences in March 2025:

  • The 37th Annual Roth Conference is being held on March 16-18, 2025, at the Laguna Cliffs Marriott Resort in Dana Point, CA. On March 17th, management will host one-on-one meetings and is scheduled for a Fireside Chat on the same day starting at 10 a.m. PT (1:00 p.m. ET). The live webcast is available on HBIO’s website at . Investors interested in scheduling a one-on-one meeting can contact .



  • The KeyBanc Capital Markets Healthcare Forum is a virtual event scheduled for March 19, 2025. Management will host one-on-one meetings and is also scheduled for a Fireside Chat with Paul Knight, KeyBanc Capital Markets, on the same day starting at 3:45 p.m. ET. The live webcast is available on HBIO’s website at . Investors interested in scheduling a one-on-one meeting can contact .

About Harvard Bioscience, Inc.

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world. For more information, please visit our website at  

Company Contact: 

Harvard Bioscience 

Jennifer Cote, Chief Financial Officer 

(508) 893-3120 

Investor Contacts: 

Three Part Advisors 

Sandy Martin / Erol Girgin

 

(214) 616-2207 



EN
12/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harvard Bioscience Inc.

 PRESS RELEASE

Harvard Bioscience, Inc. to Participate in Two Investor Conferences in...

Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025 HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two investor conferences in March 2025: The 37th Annual Roth Conference is being held on March 16-18, 2025, at the Laguna Cliffs Marriott Resort in Dana Point, CA. On March 17th, management will host one-on-one meetings and is scheduled for a Fireside Chat on the same day starting at ...

 PRESS RELEASE

Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financi...

Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, said, “Our fourth quarter saw sequential strengthening in pre-clinical revenues across all regions, while our cellular and molecular technology (CMT) revenues were down slightly from the third quarter, primarily due to reduced purchasing by US academic customers. As expected, ou...

 PRESS RELEASE

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Or...

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 17-20, 2025, in Orlando. Building upon its comprehensive product portfolio, these latest developments open promising new avenues for progressing prec...

 PRESS RELEASE

Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference C...

Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register . Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to ...

 PRESS RELEASE

Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Confer...

Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference HOLLISTON, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Micro Cap Virtual Conference on January 22nd, 2025, with a presentation time of 10:00 am ET. The presentation will be webcast live and can be accessed through the investor relations section of the Harvard Bioscience website: . A replay will be available on the company’s webs...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch